Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study.

BACKGROUND Exenatide is the first of a new class of agents known as incretin mimetics that are in development for the treatment of type 2 diabetes. Exenatide has been shown to reduce fasting and postprandial glucose in patients with type 2 diabetes, as well as provide sustained reductions in hemoglobin A 1c (HbA 1c). This study was designed to assess the dose dependencies of the glucoregulatory effects and tolerability of exenatide when added to diet and exercise or metformin monotherapy in patients with type 2 diabetes. METHODS In this randomized, triple-blinded, placebo-controlled Phase 2 clinical trial, 156 patients were randomized to placebo or exenatide at 2.5, 5.0, 7.5, or 10.0 microg administered b.i.d. for 28 days. RESULTS After 28 days of therapy, exenatide was associated with significant (P < 0.0001, linear contrast testing), dose-dependent reductions in HbA 1c (0.1 +/- 0.1%, -0.3 +/- 0.1%, -0.4 +/- 0.1%, +/-0.5 +/- 0.0%, and -0.5 +/- 0.1% for placebo and 2.5, 5.0, 7.5, and 10.0 microg b.i.d. exenatide, respectively) and significant (P = 0.0006, linear contrast testing) reductions in fasting plasma glucose (+6.8 +/- 4.1, -20.1 +/- 5.2, -21.2 +/- 3.9, -17.7 +/- 4.8, and -17.3 +/- 4.4 mg/dL for placebo and 2.5, 5.0, 7.5, and 10.0 microg b.i.d. exenatide, respectively) by Day 28. These reductions were similar for patients treated with diet/exercise and those treated with metformin. In addition, patients receiving exenatide exhibited dose-dependent reductions in body weight (0.0 +/- 0.3, -0.7 +/- 0.3, -0.7 +/- 0.2, -1.4 +/- 0.3, and -1.8 +/- 0.3 kg for placebo and 2.5, 5.0, 7.5, and 10.0 microg b.i.d. exenatide, respectively; P < 0.01 for 7.5 and 10.0 microg b.i.d. exenatide doses compared with placebo) at Day 28. The most common adverse event was mild-to-moderate nausea that was dose-dependent (seven of 123 patients randomized to exenatide withdrew from the study because of gastrointestinal effects). CONCLUSIONS Exenatide dose-dependently improved glycemic control and reduced body weight over 28 days in patients with type 2 diabetes treated with diet/exercise or metformin.

[1]  Dennis D. Kim,et al.  Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. , 2003, The Journal of clinical endocrinology and metabolism.

[2]  Dennis D. Kim,et al.  Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. , 2005, Diabetes care.

[3]  M. Buysschaert,et al.  Troglitazone in combination with sulphonylurea improves glycaemic control in Type 2 diabetic patients inadequately controlled by sulphonylurea therapy alone , 1999, Diabetic medicine : a journal of the British Diabetic Association.

[4]  D. Schimel,et al.  Efficacy and Safety of Acarbose in Insulin-Treated Patients With Type 2 Diabetes , 1998, Diabetes Care.

[5]  J. Egan,et al.  The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. , 2002, The Journal of clinical endocrinology and metabolism.

[6]  B. Wolffenbuttel,et al.  A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group. , 1999, Diabetes care.

[7]  A. Young,et al.  Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). , 1999, Diabetes.

[8]  G. Shulman,et al.  Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. , 1998, The New England journal of medicine.

[9]  A. Baron,et al.  Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes. , 2003, Current opinion in investigational drugs.

[10]  Dennis D. Kim,et al.  Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. , 2003, Diabetes care.

[11]  Rury R Holman,et al.  Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). , 2002, Diabetes care.

[12]  B. Göke,et al.  Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. , 1993, The Journal of biological chemistry.

[13]  Z. Ota,et al.  The Effect of an α-Glucosidase Inhibitor and Insulin on Glucose Metabolism and Lipid Profiles in Non-Insulin-Dependent Diabetes Mellitus , 1996 .

[14]  M. Muggeo,et al.  Combination treatment with metformin and glibenclamide versus single-drug therapies in type 2 diabetes mellitus: a randomized, double-blind, comparative study. , 2003, Metabolism: clinical and experimental.

[15]  K. Murphy,et al.  A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. , 2002, Diabetes care.

[16]  H. Nawata,et al.  Effects of a New Oral Hypoglycaemic Agent (CS‐045) on Metabolic Abnormalities and Insulin Resistance in Type 2 Diabetes , 1994, Diabetic medicine : a journal of the British Diabetic Association.

[17]  J. Ph,et al.  Dose response studies. II. Analysis and interpretation. , 1995 .

[18]  M. Marre,et al.  Influence of initial hyperglycaemia, weight and age on the blood glucose lowering efficacy and incidence of hypoglycaemic symptoms with a single‐tablet metformin–glibenclamide therapy (Glucovance®) in type 2 diabetes , 2003, Diabetes, obesity & metabolism.

[19]  J. Rosenstock,et al.  Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. , 2000, JAMA.

[20]  C. Bogardus,et al.  The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. , 1999, The Journal of clinical investigation.

[21]  G. Warsi,et al.  Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes , 2002, Diabetes/metabolism research and reviews.

[22]  G. Grunberger,et al.  Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. , 2001, Diabetes care.

[23]  A. Young,et al.  Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. , 2001, Metabolism: clinical and experimental.

[24]  I. Kourides,et al.  Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents: a randomized controlled trial. , 2003, Archives of internal medicine.

[25]  S. Madsbad,et al.  Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1‐year multicentre study , 2001, Diabetic medicine : a journal of the British Diabetic Association.

[26]  Bo Ahrén,et al.  Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. , 2002, Diabetes care.

[27]  N. Greig,et al.  Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. , 2000, Endocrinology.

[28]  S. Pocock,et al.  Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.

[29]  S. Bonner-Weir,et al.  Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. , 1999, Diabetes.

[30]  Dennis D. Kim,et al.  Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. , 2005, Diabetes care.

[31]  D. Cavan,et al.  Treating obese patients with poorly controlled diabetes: confessions of an insulin therapist , 1999, Diabetes/metabolism research and reviews.

[32]  M. Rendell,et al.  Combination therapy with pioglitazone plus metformin or sulfonylurea in patients with Type 2 diabetes: influence of prior antidiabetic drug regimen. , 2003, Journal of diabetes and its complications.

[33]  B. Portha,et al.  Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. , 2002, Diabetes.

[34]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[35]  S. Inzucchi.  Oral antihyperglycemic therapy for type 2 diabetes: scientific review. , 2002, JAMA.

[36]  Dennis D. Kim,et al.  Effectiveness of progressive dose‐escalation of exenatide (exendin‐4) in reducing dose‐limiting side effects in subjects with type 2 diabetes , 2004, Diabetes/metabolism research and reviews.

[37]  S. Mudaliar,et al.  Insulin therapy in type 2 diabetes. , 2001, Endocrinology and metabolism clinics of North America.

[38]  Dennis D. Kim,et al.  Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. , 2004, Diabetes.

[39]  Robert M. Anderson,et al.  5. Prevention or Delay of Type 2 Diabetes , 2016, Diabetes Care.

[40]  B. Portha,et al.  Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. , 2001, Diabetes.

[41]  P. Raskin,et al.  Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin. , 2003, Diabetes care.

[42]  B. Willms,et al.  Comparison of acarbose and metformin in patients with Type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo‐controlled study , 1999, Diabetic medicine : a journal of the British Diabetic Association.

[43]  H. Lebovitz,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Rosiglitazone Monotherapy Is Effective in Patients with Type 2 Diabetes , 1999 .